Pfizer's Talzenna, or talazoparib, has been approved by the European Commission as a treatment for advanced-stage breast cancer patients with inherited BRCA gene mutation. The decision was backed by data from a late-stage trial in which patients who were treated with Talzenna had their disease progression slow by 46% versus chemotherapy.
Sign up for FDLI SmartBrief
News for the food and drug law community
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.